Home / Stocks / Jagsonpal Pharmaceuticals
JAGSNPHARM

Jagsonpal Pharmaceuticals Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹210.42

Change

+2.15 (1.03%)

Open

₹208.1

Prev. Close

₹208.27

Day High

₹213.4

Day Low

₹205.96

Volume Analysis

Traded

35,178

Delivered

17,334

Delivery %

49.28%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (20.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (16.4%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹221.34 ₹217.37 ₹213.9 ₹209.93 ₹206.46 ₹202.49 ₹199.02
Fibonacci ₹217.37 ₹214.53 ₹212.77 ₹209.93 ₹207.09 ₹205.33 ₹202.49
Camarilla ₹212.47 ₹211.78 ₹211.1 ₹209.93 ₹209.74 ₹209.06 ₹208.37

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+9.29%

1 Week

-2.91%

1 Month

-3.44%

3 Months

-11.04%

6 Months

+0.24%

1 Year

+2.23%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹72.57

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

15.68%

Net margin 14.98% × asset turnover 0.91x × equity multiplier 1.15x

Company Overview

Sector

Healthcare

Market Cap

₹1,402 Cr

Book Value

₹36.4

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Jagsonpal Pharmaceuticals holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 68/100. The strongest factor is Financial Strength (100/100), while Valuation (28/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%). Strong 3-year EPS growth (16.4%).

TopFund Score — Fundamentals Quality

68/100 — Good

Data confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

64

Valuation

28

Cash Flow

83

Corporate Governance

80

Momentum

52

Institutional Ownership

53

Business Quality

85

Risk & Volatility

64

Liquidity

30

From Screener.in

  • +Company is almost debt free.
  • −Stock is trading at 5.82 times its book value

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Earning call transcript for Jagsonpal Pharmaceuticals Limited Q2 FY 27 Earning Conference Call on October 29, 2026 at 2:00 P.M

Audio recording of Jagsonpal Pharmaceuticals’ Q2 FY27 earnings conference call uploaded on website.

Newspaper Publication providing extracts of Unaudited Results of Company for the quarter and half ended September 30, 2026.

Press Release for Unaudited Financial Results for the quarter September 30, 2026

Jagsonpal reported Q2FY27 revenue of ₹964 million, H1 PAT up 10.3%, plus acquisition updates.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026
Sales + 58 47 43 61 75 74 59 76 74 73 64 82 96
Expenses + 49 44 41 51 58 58 50 61 58 57 53 65 79
Operating Profit 8 3 3 10 16 16 9 14 16 16 11 17 17
OPM % 14.0% 7.0% 6.0% 17.0% 22.0% 21.0% 15.0% 19.0% 22.0% 22.0% 17.0% 21.0% 18.0%
Other Income + 2 3 2 -2 2 26 3 3 3 1 3 3 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 1 2 2 2 2 2 2 2 2 2
Profit before tax 10 5 5 7 15 39 9 14 17 15 12 18 16
Tax % 25.0% 25.0% 22.0% 25.0% 25.0% 17.0% 24.0% 25.0% 25.0% 25.0% 25.0% 25.0% 25.0%
Net Profit + 7 4 4 5 11 32 7 11 13 11 9 13 12
EPS in Rs 1 1 1 1 2 5 1 2 2 2 1 2 2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -4 -21 -22 2 29 57 35 23 0 -1 10 9 —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 138 143 144 127 167 159 188 218 237 209 269 287
Expenses + 129 132 138 138 157 150 169 192 203 186 218 229
Operating Profit 9 12 6 -11 9 9 19 26 34 23 51 58
OPM % 6.0% 8.0% 4.0% -9.0% 6.0% 5.0% 10.0% 12.0% 14.0% 11.0% 19.0% 20.0%
Other Income + 0 1 13 0 1 3 4 3 2 9 28 10
Interest 4 5 3 1 1 1 1 0 0 1 1 1
Depreciation 3 3 2 0 1 1 1 2 1 2 8 9
Profit before tax 2 4 14 -12 9 9 22 27 35 30 70 58
Tax % 30.0% 20.0% 18.0% -1.0% 20.0% 16.0% 22.0% 29.0% 23.0% 25.0% 21.0% 25.0%
Net Profit + 1 3 12 -12 7 8 17 19 27 22 55 43
EPS in Rs 0 1 2 -2 1 1 3 3 4 3 8 6
Dividend Payout % 22.0% 8.0% 2.0% -2.0% 9.0% 17.0% 15.0% 56.0% 49.0% 59.0% 30.0% 62.0%
Sales growth -4 4 0 -12 32 -5 19 16 9 -12 29 7

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026
Reserves 82 85 97 85 91 98 109 120 146 174 227 263 227
Borrowings + 39 38 8 8 4 5 7 0 6 9 9 8 9
Other Liabilities + 19 22 25 23 28 31 35 31 30 21 29 32 68
Total Liabilities 154 159 143 130 136 147 164 164 195 217 278 317 318
Fixed Assets + 52 52 22 21 22 22 26 23 24 9 94 85 105
CWIP 0 0 0 3 4 4 0 0 0 0 0 0 0
Investments 0 0 0 0 0 11 15 51 1 0 0 0 0
Other Assets + 102 108 121 105 110 109 123 91 170 208 184 231 213
Total Assets 154 159 143 130 136 147 164 164 195 217 278 317 318
Equity Capital 13 13 13 13 13 13 13 13 13 13 13 13 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + 4 9 -3 -2 31 11 28 7 47 35 55 47
Cash from Investing Activity + 0 -2 41 -3 -1 -11 -2 -26 -58 -25 -45 -36
Cash from Financing Activity + -1 -6 -34 -1 -6 -1 -7 -18 0 -9 -12 -12
Net Cash Flow 2 1 5 -6 24 0 19 -36 -11 2 -2 -1
Free Cash Flow 4 6 40 -5 30 12 28 6 48 35 90 47
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 53 83 -6 14 311 150 164 54 158 189 124 101

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 68.48% → 68.82%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 30.16% 30.33% 30.01% 29.63% 30.1% 30.11% 30.12% 30.25% 30.34% 29.44% 28.04% 27.4%
Promoters 68.48% 68.09% 68.04% 67.98% 67.82% 67.77% 67.65% 67.54% 67.39% 67.89% 69.06% 68.82%
FII 0.53% 0.73% 1.1% 2.3% 2.1% 2.1% 2.17% 2.12% 2.12% 2.44% 2.3% 2.13%
DII 0.82% 0.84% 0.84% 0.11% 0.0% 0.0% 0.05% 0.08% 0.15% 0.22% 0.62% 1.64%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Jagsonpal Pharmaceuticals (this stock) 1,402 — 5.82 —
Fermenta Biotech Ltd. 1,367 29.4 3.27 17.3%
Anlon Healthcare Limited 1,348 37.8 5.25 18.4%
Amrutajan Health Ltd 1,461 71.7 13.58 20.0%
Shalby Limited 1,317 33.6 1.29 2.45%
Bharat Parenterals Ltd. 1,522 1227.0 4.59 -2.54%
Kopran Ltd 1,281 32.6 2.44 4.91%

Which Mutual Funds Hold Jagsonpal Pharmaceuticals?

Frequently Asked Questions about Jagsonpal Pharmaceuticals

Community Sentiment

What are other investors saying about Jagsonpal Pharmaceuticals?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.